ArticleFrontiers in medicine2025
Thermal ablation combined with percutaneous injection of amphotericin B for the treatment of chronic pulmonary aspergillosis: a case series.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Combined intracavitary, systemic antifungal and surgical treatment of Chronic Pulmonary Aspergillosis: experience from an immunocompromised patient.Medical mycology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the efficacy of thermal ablation combined with percutaneous injection of amphotericin B in the treatment of chronic pulmonary aspergillosis. Case reports: Case 1 was a 66-year-old female, whose computed tomography (CT) showed a space-occupying lesion in the upper lobe of the right lung. Case 2 was a 48-year-old female, and her CT scan revealed an eccentric cavity in the upper right lung accompanied by the formation of an aspergilloma. Case 3 was a 40-year-old male, and his CT indicated the formation of an aspergilloma within the cavity in the upper lobe of the left lung. All three patients had a history of pulmonary tuberculosis and were diagnosed with pulmonary aspergillosis in other hospitals. Due to the unsatisfactory effect of oral triazole drugs, they finally came to our hospital to receive the treatment of thermal ablation combined with percutaneous injection of amphotericin B. They recovered well after the operation without significant complications. Results: During the follow-up period ranging from 1 month to 2 years after discharge, the patients reported no discomfort symptoms such as hemoptysis or chest pain. CT scans showed that the lesions were stable and even absorbed compared with those before treatment. The patients recovered well. Conclusion: The combination of thermal ablation and percutaneous injection of amphotericin B in the treatment of chronic pulmonary aspergillosis can significantly improve the clinical symptoms of patients and enhance their quality of life. It may become a treatment method for chronic pulmonary aspergillosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.